Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Project cooperationUpdated on 9 April 2026

Portfolio Company Collaboration: 20/20 OptimEyes Technologies

Renaud Jacquemart

CEO at Omnium Global

Burlington, Canada

About

20/20 OptimEyes Technologies is developing a pipeline of long-acting therapies that treat diseases of the eye, lungs, bladder, and more by delivering proven drugs directly to mucosal surfaces—safely, effectively, and with less frequent dosing. Our lead program is a once-weekly eye drop for glaucoma, with additional candidates in ophthalmology, oncology, and respiratory segments. We are open to exploring collaborations with any novel small molecule assets that could benefit from our mucosal drug delivery platform.

Stage

  • Execution

Topic

  • Biotech, Pharma and Cosmetics

Type

  • Research
  • Technical

Organisation

Omnium Global

SME

Toronto, Canada

Similar opportunities